Detail

Study ID: Pfizer C3571002 Infant Conjugate Pneumococcal Vaccine

Title:

A PHASE 2, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE GIVEN WITH, OR SEPARATELY FROM, 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS

Description:
4 Key Inclusion/Exclusion Criteria including Age Range If Applicable:Healthy infants 42-98 days of ageHas not received a pneumococcal vaccineHas not received >1 dose of Hepatitis B vaccineDoes not have a significant medical disorder
Location:
Sioux Falls Region
Principal Investigator:
Archana Chatterjee, MD, PhD
Disease:
Lung
Stage:
Phase II
Status:
Active - Open to Accrual